Naturally occurring HCA1 missense mutations result in loss of function: Potential impact on lipid deposition

Journal of Lipid Research

Volumn 54, Issue 3, 2013, Pages 823-830

  Doyle, Jamie R ^a   Lane, Jacqueline M ^a   Beinborn, Martin ^a   Kopin, Alan S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Constitutive activity; Dyslipidemia; G proteincoupled receptor; Hydroxycarboxylic acid receptor; OP9 cell; Polymorphism

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HYDROXY CARBOXYLIC ACID RECEPTOR 1; LUCIFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CELL LINE; CELL STRAIN HEK293; CELL SURFACE; CONTROLLED STUDY; CULTURE MEDIUM; GENE SILENCING; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; LIGAND BINDING; LIPID METABOLISM; LIPID STORAGE; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION; THIN LAYER CHROMATOGRAPHY; TRANSIENT EXPRESSION;

CARRIER PROTEINS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPID METABOLISM; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; RNA, SMALL INTERFERING;

EID: 84874103412     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M034660     Document Type: Article

References (42)

1. Ge, H., J. Weiszmann, J. D. Reagan, J. Gupte, H. Baribault, T. Gyuris, J. L. Chen, H. Tian, and Y. Li. 2008. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. J. Lipid Res. 49 : 797-803.
2. Liu, C., J. Wu, J. Zhu, C. Kuei, J. Yu, J. Shelton, S. W. Sutton, X. Li, S. J. Yun, T. Mirzadegan, et al. 2009. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J. Biol. Chem. 284 : 2811-2822.
3. Offermanns, S., S. L. Colletti, T. W. Lovenberg, G. Semple, A. Wise, and A. P. IJzerman. 2011. International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classifi cation of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev. 63 : 269-290.
4. Ahmed, K., S. Tunaru, and S. Offermanns. 2009. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol. Sci. 30 : 557-562.
5. Offermanns, S. 2006. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci. 27 : 384-390.
6. Wise, A., S. M. Foord, N. J. Fraser, A. A. Barnes, N. Elshourbagy, M. Eilert, D. M. Ignar, P. R. Murdock, K. Steplewski, A. Green, et al. 2003. Molecular identifi cation of high and low affi nity receptors for nicotinic acid. J. Biol. Chem. 278 : 9869-9874.
7. Cai, T. Q., N. Ren, L. Jin, K. Cheng, S. Kash, R. Chen, S. D. Wright, A. K. Taggart, and M. G. Waters. 2008. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem. Biophys. Res. Commun. 377 : 987-991.
8. Ahmed, K., S. Tunaru, C. Tang, M. Muller, A. Gille, A. Sassmann, J. Hanson, and S. Offermanns. 2010. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab. 11 : 311-319.
9. Al-Fulaij, M. A., Y. Ren, M. Beinborn, and A. S. Kopin. 2007. Identifi cation of amino acid determinants of dopamine 2 receptor synthetic agonist function. J. Pharmacol. Exp. Ther. 321 : 298-307.
10. Fortin, J. P., J. C. Schroeder, Y. Zhu, M. Beinborn, and A. S. Kopin. 2010. Pharmacological characterization of human incretin receptor missense variants. J. Pharmacol. Exp. Ther. 332 : 274-280.
11. Doran, A. C., N. Meller, A. Cutchins, H. Deliri, R. P. Slayton, S. N. Oldham, J. B. Kim, S. R. Keller, and C. A. McNamara. 2008. The helix-loop-helix factors Id3 and E47 are novel regulators of adiponectin. Circ. Res. 103 : 624-634.
12. Wolins, N. E., B. K. Quaynor, J. R. Skinner, A. Tzekov, C. Park, K. Choi, and P. E. Bickel. 2006. OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. J. Lipid Res. 47 : 450-460.
13. Doyle, J. R., J. P. Fortin, M. Beinborn, and A. S. Kopin. 2012. Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways. J. Pharmacol. Exp. Ther. 342: 318-326.
14. Fortin, J. P., Y. Zhu, C. Choi, M. Beinborn, M. N. Nitabach, and A. S. Kopin. 2009. Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function. Proc. Natl. Acad. Sci. USA. 106 : 8049-8054.
15. Ehrhardt, C., M. Schmolke, A. Matzke, A. Knoblauch, C. Will, V. Wixler, and S. Ludwig. 2006. Polyethylenimine, a cost-effective transfection agent. Signal Transduct. 6 : 179-184.
16. Boussif, O., F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J. P. Behr. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA. 92 : 7297-7301.
17. Al-Fulaij, M. A., Y. Ren, M. Beinborn, and A. S. Kopin. 2008. Pharmacological analysis of human D1 and D2 dopamine receptor missense variants. J. Mol. Neurosci. 34 : 211-223.
18. Conklin, B. R., Z. Farfel, K. D. Lustig, D. Julius, and H. R. Bourne. 1993. Substitution of three amino acids switches receptor specifi city of Gq alpha to that of Gi alpha. Nature. 363 : 274-276.
19. Fortin, J. P., L. Ci, J. Schroeder, C. Goldstein, M. C. Montefusco, I. Peter, S. E. Reis, G. S. Huggins, M. Beinborn, and A. S. Kopin. 2010. The mu-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs. Mol. Pharmacol. 78 : 837-845.
20. Kostenis, E., L. Martini, J. Ellis, M. Waldhoer, A. Heydorn, M. M. Rosenkilde, P. K. Norregaard, R. Jorgensen, J. L. Whistler, and G. Milligan. 2005. A highly conserved glycine within linker I and theextreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor-to-effector specifi city. J. Pharmacol. Exp. Ther. 313 : 78-87.
21. Liscum, L., and J. R. Faust. 1987. Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fi broblasts. J. Biol. Chem. 262 : 17002-17008.
22. Goldstein, J. L., S. K. Basu, and M. S. Brown. 1983. Receptormediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98 : 241-260.
23. Conn, P. M., and A. Ulloa-Aguirre. 2010. Traffi cking of G-proteincoupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol. Metab. 21 : 190-197.
24. Hu, J., Y. Wang, X. Zhang, J. R. Lloyd, J. H. Li, J. Karpiak, S. Costanzi, and J. Wess. 2010. Structural basis of G protein-coupled receptor-G protein interactions. Nat. Chem. Biol. 6 : 541-548.
25. Wess, J. 1998. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol. Ther. 80 : 231-264.
26. Lefkowitz, R. J., S. Cotecchia, P. Samama, and T. Costa. 1993. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14 : 303-307.
27. Beinborn, M., Y. Ren, M. Blaker, C. Chen, and A. S. Kopin. 2004. Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol. Pharmacol. 65 : 753-760.
28. Kuei, C., J. Yu, J. Zhu, J. Wu, L. Zhang, A. Shih, T. Mirzadegan, T. Lovenberg, and C. Liu. 2011. Study of GPR81, the lactate receptor, from distant species identifi es residues and motifs critical for GPR81 functions. Mol. Pharmacol. 80 : 848-858.
29. Liu, C., C. Kuei, J. Zhu, J. Yu, L. Zhang, A. Shih, T. Mirzadegan, J. Shelton, S. Sutton, M. A. Connelly, et al. 2012. 3,5-Dihydroxybenzoic acid, a specifi c agonist for HCA1, inhibits lipolysis in adipocytes. J. Pharmacol. Exp. Ther. 341: 794-801.
30. Ntambi, J. M., and K. Young-Cheul. 2000. Adipocyte differentiation and gene expression. J. Nutr. 130 : 3122S-3126S.
31. Wabitsch, M., R. E. Brenner, I. Melzner, M. Braun, P. Moller, E. Heinze, K. M. Debatin, and H. Hauner. 2001. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int. J. Obes. Relat. Metab. Disord. 25: 8-15.
32. Rodriguez, A. M., C. Elabd, F. Delteil, J. Astier, C. Vernochet, P. Saint-Marc, J. Guesnet, A. Guezennec, E. Z. Amri, C. Dani, et al. 2004. Adipocyte differentiation of multipotent cells established from human adipose tissue. Biochem. Biophys. Res. Commun. 315 : 255-263.
33. Jeninga, E. H., A. Bugge, R. Nielsen, S. Kersten, N. Hamers, C. Dani, M. Wabitsch, R. Berger, H. G. Stunnenberg, S. Mandrup, et al. 2009. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81). J. Biol. Chem. 284 : 26385-26393.
34. Jo, J., O. Gavrilova, S. Pack, W. Jou, S. Mullen, A. E. Sumner, S. W. Cushman, and V. Periwal. 2009. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLOS Comput. Biol. 5 : e1000324.
35. Arner, E., P. O. Westermark, K. L. Spalding, T. Britton, M. Ryden, J. Frisen, S. Bernard, and P. Arner. 2010. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes. 59 : 105-109.
36. Arner, P., S. Bernard, M. Salehpour, G. Possnert, J. Liebl, P. Steier, B. A. Buchholz, M. Eriksson, E. Arner, H. Hauner, et al. 2011. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature. 478 : 110-113.
37. Hoffstedt, J., E. Arner, H. Wahrenberg, D. P. Andersson, V. Qvisth, P. Lofgren, M. Ryden, A. Thorne, M. Wiren, M. Palmer, et al. 2010. Regional impact of adipose tissue morphology on the metabolic profi le in morbid obesity. Diabetologia. 53 : 2496-2503.
38. Meissburger, B., L. Stachorski, E. Roder, G. Rudofsky, and C. Wolfrum. 2011. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans. Diabetologia. 54 : 1468-1479.
39. Feingold, K. R., A. Moser, J. K. Shigenaga, and C. Grunfeld. 2011. Infl ammation inhibits GPR81 expression in adipose tissue. Infl am. Res. 60 : 991-995.
40. Farooqi, I. S., and S. O'Rahilly. 2007. Genetic factors in human obesity. Obes. Rev. 8 (Suppl.): 37-40.
41. Gibson, G. 2011. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13 : 135-145.
42. Seifert, R., and K. Wenzel-Seifert. 2002. Constitutive activity of G-proteincoupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366 : 381-416